Management tracks: Bourla to succeed Read as Pfizer chair; plus Phathom, OnKure, Forma, Beam, Noven, Cerebral, Alpha Tau and InsightRX
Ian Read will retire as chairman of Pfizer Inc. (NYSE:PFE) on Dec. 31, with CEO Albert Bourla his successor. Read has been with the pharma since 1978, becoming CEO in 2010 and chairman in 2011. Bourla replaced Read as CEO on Jan. 1. Prior to that, Bourla spent a year as COO and three years leading Pfizer’s most productive business division by new drug launches (see “Bourla’s Breadcrumbs to Value” & “With Mylan Deal, Pfizer Seeks Faster Growth via Innovation Focus”).
Phathom Pharmaceuticals Inc. hired Terrie Curran as CEO and appointed her to its board. Curran, who is president, global inflammation and immunology at Celgene, will succeed David Socks, who will subsequently serve as interim CFO while continuing to serve on the board. The biopharmaceutical company also appointed Michael Cola, Heidi Kunz and Chris Slavinsky to the board. Curran’s post becomes effective when the acquisition of Celgene Corp. (NASDAQ:CELG) by Bristol-Myers Squibb Co. (NYSE:BMY) closes...